Adcetris improves PFS by 27.4 months in first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) reported detailed data from the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing peripheral T cell lymphoma (PTCL) showing that Adcetris brentuximab vedotin plus chemotherapy improved median progression-free survival (PFS) per Blinded Independent Central Review (BICR) by 27.4 months at a median follow-up of 36.2 months vs. cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy (48.2 vs. 20.8 months, HR=0.71, p=0.011). Median overall survival (OS) was not reached in either arm at a median follow-up of 42.1 months (HR=0.66, p=0.0244). The double-blind, international trial enrolled 452 patients. Data were presented at the American Society of Hematology (ASH) meeting in San Diego and published in The Lancet.

The partners previously reported that Adcetris plus chemotherapy met the primary and all key secondary endpoints in ECHELON-2, but did not report detailed data (see "Adcetris Meets in Phase III for First-line PTCL")...